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Introduction: We have previously found an increased mast cell density in tendon biopsies from patients with
patellar tendinopathy compared to controls. This study examined the influence of mast cells on basic tenocyte
functions, including production of the inflammatory mediator prostaglandin E2 (PGE2), extracellular matrix
remodeling and matrix metalloproteinase (MMP) gene transcription, and collagen synthesis.
Methods: Primary human tenocytes were stimulated with an established human mast cell line (HMC-1). Extracellular
matrix remodeling was studied by culturing tenocytes in a three-dimensional collagen lattice. Survival/proliferation was
assessed with the 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium salt (MTS)
assay. Levels of mRNA for COX-2, COL1A1, MMP1, and MMP7 were determined by quantitative real-time polymerase
chain reaction (qPCR). Cox-2 protein level was assessed by Western blot analysis and type I procollagen was detected
by immunofluorescent staining. PGE2 levels were determined using an enzyme-linked immunosorbent assay (ELISA).
Results: Mast cells stimulated tenocytes to produce increased levels of COX-2 and the pro-inflammatory mediator
PGE2, which in turn decreased COL1A1 mRNA expression. Additionally, mast cells reduced the type I procollagen protein
levels produced by tenocytes. Transforming growth factor beta 1 (TGF-β1) was responsible for the induction of Cox-2
and PGE2 by tenocytes. Mast cells increased MMP1 and MMP7 transcription and increased the contraction of a
three-dimensional collagen lattice by tenocytes, a phenomenon which was blocked by a pan-MMP inhibitor
(Batimastat).
Conclusion: Our data demonstrate that mast cell-derived PGE2 reduces collagen synthesis and enhances expression
and activities of MMPs in human tenocytes.Introduction
Tendons are dense connective tissues, responsible for
transmitting load between muscle and bone. The primary
cell type in tendons, tenocytes, may be influenced by the
presence of mast cells in their microenvironment. Al-
though associations between mast cells and a number of
chronic conditions including pulmonary fibrosis [1], renal
fibrosis [2], and scleroderma [3] have been established,
very few data are available on the possible link between
mast cells and the failed tissue healing or fibrosis that is
evident in chronically injured tendon tissues. We have
previously documented a greater number of mast cells in* Correspondence: ascott@interchange.ubc.ca
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reproduction in any medium, provided the orthe tendons of patellar tendinopathy subjects compared
with healthy controls [4], and increased mast cell numbers
have also been detected in the injured rotator cuff [5]. We
also found that tendon overuse (intensive uphill treadmill
running) led to an increased density of mast cells in the
Achilles paratendon [6]. Certainly, since mast cells are
present in and around tendons, and since they possess an
arsenal of inflammatory mediators and growth factors,
they could exacerbate certain features of tendon injury or
overuse pathology such as inflammation, excessive cell
proliferation, and inappropriate matrix remodeling, con-
tributing to the formation of poorly organized repair
tissue, and ongoing injury and pain.
In this study, we utilized an in vitro culture system
using human primary tendon fibroblasts (tenocytes) andLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Sequences of the quantitative polymerase chain
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gate potential effects of mast cells on tenocyte gene ex-
pression and function. Our data provide evidence for
mechanisms by which mast cells could contribute to the
development of tendinopathy, including a transforming
growth factor beta (TGFβ)-dependent upregulation of
cyclooxygenase (COX)-2, a reduction of COL1A1 mRNA
and type I procollagen protein levels in tenocytes, and a
matrix metalloproteinases (MMP)-dependent increase in
collagen remodeling activity. The current studies sup-
port the hypothesis that inflammatory cells may be in-




Tendon fibroblasts (tenocytes) were isolated from hu-
man hamstring tendon, after obtaining informed consent
from each subject. Ethics approval was obtained from
the review board at the University of British Columbia.
Briefly, samples of healthy hamstring tendons from pa-
tients undergoing anterior cruciate ligament reconstruction
were trimmed to remove fat and muscle, washed with
phosphate-buffered saline (PBS), and enzymatically digested
with filtered 1.5 mg/ml collagenase (Clostridopeptidase A;
Sigma, Oakville, Ontario, Canada) in serum-free Dubecco’s
modified Eagle medium (DMEM; HyClone, South Logan,
Utah, USA) for 30 minutes at 37°C with shaking. Following
collagenase digestion, 1× trypsin (TrypLE™ Select; Gibco,
Life Technologies, Burlington, ON, Canada) was added for
an additional 5 minutes. The cell–collagenase–trypsin mix-
ture was then centrifuged at 1,200 rpm for 5 minutes and
the resulting cell pellet was resuspended and cultured in
DMEM supplemented with 10% fetal bovine serum (FBS),
and 1% penicillin–streptomycin at 37°C in 5.0% carbon di-
oxide. The HMC-1 cell line was originally established from a
patient with mast cell leukemia [8]. HMC-1 mast cells were
grown in RPMI 1640 media (HyClone) supplemented with
10% FBS and L-glutamine at 37°C in 5.0% carbon dioxide.
HMC-1 conditioned media and sonicate
HMC-1 cells (1.5 × 106 cells/ml media) were cultured for
24 hours in the presence or absence of serum. Cells were
centrifuged at 1,200 rpm for 5 minutes, and supernatant
was collected as HMC-1 conditioned media. For the gen-
eration of HMC-1 sonicate (mast cell sonicate (MCS)),
HMC-1 cells were cultured in the presence or absence of
indomethacin (2 μM) for 48 hours, then washed with
PBS and resuspended in serum-free DME/F-12 media
(HyClone) at a concentration of 5 × 106 cells/ml, and then
sonicated on ice for 1 minute (duty cycle 5 seconds, out-
put power 50%; Heat Systems Ultrasonics). The sonicated
mixture was centrifuged at 13,000 rpm for 10 minutes at
4°C. Supernatants were collected and stored at −80°C.Experimental conditions
Tenocytes were grown to confluence in six-well plates.
For quantitative polymerase chain reaction (qPCR) stud-
ies, cells were treated with 2 ng/ml TGF-β1 (R&D Sys-
tems, Minneapolis, MN, USA), 2 μM A83-01 (Tocris
Biosciences, Minneapolis, MN, USA), or the HMC-1
conditioned media (prepared with 10% FBS) for 2, 4, 6,
8, and 24 hours. For western blot analyses, confluent teno-
cytes were grown in the absence of FBS overnight. Cells
were then treated with TGF-β1, A83-01, and/or serum-free
mast cell conditioned media for 2, 4, 6, and 24 hours.
Cell viability
All of the inhibitors were tested for their potential toxic
effects on cells by performing the Trypan Blue exclusion
assay. For A83-01 and indomethacin, the lowest inhibi-
tory concentration that provided maximum inhibition
and full viability was used. Batimastat provided full via-
bility at the concentrations used in this study.
RNA isolation, cDNA synthesis, and real-time qPCR
Total RNA was isolated from cells using the Fermentas
GeneJET™ RNA purification kit (Thermo Scientific, Ottawa,
Ontario, Canada) as specified by the manufacturer. For
qPCR, 1 μg total RNA was converted to cDNA using a
High Capacity cDNA Reverse Transcription kit (Invitrogen,
Burlington, ON, Canada). qPCR was performed with SYBR
Green PCR Mix from Roche (Roche Applied Science, Laval,
Quebec, Canada). Samples were run in triplicate to ensure
reproducibility of the results. For internal control, GAPDH
was used as the housekeeping gene. The forward and
reverse primers are presented in Table 1.
Western blotting
Tenocytes were lysed in solubilization buffer (10% Tris–
HCl pH 7.7, 10% Triton X-100, 10% glycerol, 2% NaCl,
0.005% ethylenediamine tetraacetic acid, protease and
phosphatase inhibitors), sonicated, and centrifuged at
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sured using the BCA Bicinchoninic acid assay (Thermo
Scientific, Rockford, IL, USA). After boiling with the gel
loading dye (10% glycerol, 62.5 mM Tris–HCl pH 6.8, 2%
SDS, Bromophenol Blue), equal amounts of protein (40 to
50 μg) were separated by SDS-PAGE electrophoresis. The
resolved proteins were transferred electrophoretically onto
nitrocellulose membrane (Bio-Rad, Mississauga, Ontario,
Canada) by wet transfer. The membrane was incubated for
45 minutes at room temperature with blocking solution (5%
BSA, Tris base pH 7.4, 0.05% Tween-20) and then incubated
with a 1:200 dilution of a goat polyclonal antibody to Cox-2
(C-20, sc-1745; Santa Cruz, Dallas, Texas, USA) overnight at
4°C. The membranes were washed in Tris-buffered saline,
0.05% Tween-20 and incubated with a horseradish peroxid-
ase goat secondary antibody (Dako, Burlington, Ontario,
Canada) at a 1:2,500 dilution in Tris-buffered saline, 0.05%
Tween-20 for 1 hour at room temperature. After washing,
proteins were incubated with an electrochemiluminescent
detection kit (Supersignal® West Femto Maximum Sensitivity
Substrate; Thermo Scientific, Rockford, IL, USA), and de-
tected using Perkin Elmer’s Geliance 600 Imaging System
and GeneSnap from SynGene software.
Immunohistochemistry
Tenocytes were grown to confluence in an eight-well glass
slide (Lab-Tek®II Chamber Slide™ System; Nalge Nunc
International Corp., Rochester, NY, USA). Cells were either
untreated or treated with HMC-1 conditioned media for
24 hours. For type I procollagen immunostaining, cells
were fixed with 5% buffered formalin for 20 minutes,
washed with PBS, blocked in blocking buffer (1% FBS and
0.2% Tween-20 in PBS) for 30 minutes, permeabilized with
0.4% Triton X-100 for 10 minutes, and then washed and in-
cubated with 1:500 dilution of a mouse monoclonal anti-
body to type I procollagen (M-38-c; Developmental Studies
Hybridoma Bank, University of Iowa, Iowa City, IA, USA)
in blocking buffer for 2 hours. Cells were then washed and
incubated with 1:500 dilution of the Alexa Fluor® 488 goat
anti-mouse secondary antibody (Invitrogen) in blocking
buffer for 30 minutes at room temperature in the dark. Nu-
clei were visualized with Hoechst (Invitrogen) diluted to
1:10,000 in PBS for 2 minutes at room temperature. Stained
cells were washed, mounted using aqueous mounting
media (Immu-mount™; Thermo Scientific), and viewed
using a Zeiss Axio Observer A1 fluorescent microscope
equipped with a Zeiss AxioCam Lcm1 camera. The Zeiss
AxioVision SE64 Rel. 4.8 software was used for taking pic-
tures. The fluorescent signal was quantified using the open
source software CellProfiler [9] as described previously
[10]. Briefly, the mean arbitrary fluorescence intensity unit
of each cell was first calculated based on the fluorescent in-
tensity of the total pixels within the cell. A total of 600 cells
were analyzed for each condition, and the mean of meanarbitrary fluorescence intensity units were then calculated
based on the total number of cells analyzed per condition.
Enzyme-linked immunosorbent assay
Tenocytes were grown to confluence in 24-well plates. Cells
were pretreated with A83-01 (2 μM) or indomethacin
(2 μM) for 1 hour. Following pretreatment, cells were either
left untreated or were treated with mast cell conditioned
media in the presence or absence of the above inhibitors for
6 hours. Plates were washed three times with PBS, and
400 μl FBS-free DMEM was added to each plate for an add-
itional 24 hours, following which the tenocyte conditioned
media was collected and stored at −80°C for prostaglandin
E2 (PGE2) enzyme-linked immunosorbent assay (ELISA).
The PGE2 ELISA was performed using the Prostaglandin E2
EIA kit – Monoclonal (Cayman Chemical, Ann Arbor, MI,
USA), according to the manufacturer’s instructions.
Three-dimensional tenocyte-populated collagen matrix
PureCol (Bovine type I collagen solution, 3 mg/ml) was ob-
tained from Advanced Biomatrix (San Diego, CA, USA).
The tenocyte-populated collagen gel solution was prepared
by mixing PureCol, 5× DMEM (pH 7.4), and tenocytes.
The final concentration of each component in the mixture
was 1× DMEM, 2.1 mg/ml PureCol, and 5 × 105 tenocytes/
ml. Gels were cast in 24-well plates. In each well, 450 μl of
the above gel preparation (containing 2.5 × 105 tenocytes)
was mixed with either 50 μl serum-free DME/F-12, or
50 μl of the serum free MSC (extracted from 2.5 × 105 mast
cells). TGF-β1 (1 to 2 ng/ml), A83-01 (2 μM), indometh-
acin (2 μM), and batimastat (1, 2, or 5 μM) were directly
added to the gel mixture before polymerization. Gels were
allowed to polymerize at 37°C for 30 minutes and, once po-
lymerized 500 μl serum-free DME/F-12 was added to each
well. For the collagen gel contraction assay, the gels were
incubated at 37°C overnight and were released the follow-
ing day using sterile 20 μl pipette tips to go around the
edges of the wells in order to detach the gels from the sides.
Gels were scanned daily using an image scanner (V500;
Epson) and the area of each gel was measured with image
processing software (Image J, NIH, Bethesda, MD, USA).
The data for each time point were expressed as percent
area relative to the initial area at day 0.
For the MMP1 and MMP7 expression studies, RNA was
extracted from the gels as follows. Gels were cast as above
and cultured for 24 and 48 hours without being released.
At the end of each time point, gels were snap frozen in
liquid nitrogen, and stored at −80°C. The frozen samples
were pulverized with a mikro-Dismembrator S (Sartorius,
Mississauga, ON, Canada) at 3,000 rpm for 30 seconds
and the RNA was extracted using Trizol reagent (Life
Technologies, Mississauga, ON, Canada), and purified
using the Fermentas GeneJET™ RNA purification kit
(Thermo Scientific) as specified by manufacturer.
Figure 1 Mast cells promote the survival/proliferation of
human tenocytes. Cells were cultured in the presence or absence
of HMC-1 conditioned media (cond med) for 24 and 48 hours. The
MTS assay revealed a time-dependent effect of mast cells on the sur-
vival/proliferation of tenocytes. Bars show the mean ± standard error
of the mean of three experiments. Mann–Whitney U test, *P <0.001
relative to control.
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Tenocytes were serum starved overnight. Cells were either
left untreated or treated with serum-free HMC-1 condi-
tioned media for 24 and 48 hours. MTS/PMS reagent
(Promega, Madison, WI, USA) was prepared in PBS at 1/
0.92 mg/ml and was added at a ratio of 20:1 to cells and
plates were incubated for 3 to 4 hours. The absorbance at
490 nm was then recorded with a spectrophotometer. The
cell viability of treated cells relative to untreated cells was
expressed as a percentage for each time point.
Statistical analysis
Data were expressed as the mean ± standard error of the
mean (SEM). The Mann–Whitney U test and Student’s t
test were used to determine the significance of differ-
ences between two experimental groups. The collagen
gel contraction assay was analyzed with two-way analysis
of variance followed by Bonferroni’s post-hoc test. The
effect of Batimastat on collagen matrix contraction was
analyzed with a linear mixed model fit by restricted
maximum likelihood. P <0.05 was considered significant.
Differences in PGE2 production by tenocytes exposed to
mast cell conditioned media with/without inhibitors
(indomethacin, A83-01) were examined using one-way
analysis of variance followed by Bonferroni’s post-hoc
test with an overall alpha level set at P = 0.01.
Results
Tendinopathy is associated with increased fibroblast
hypercellularity [11]. Initial experiments therefore exam-
ined the influence of mast cells on tenocyte survival/pro-
liferation. The MTS assay revealed that mast cells
significantly enhanced the survival/proliferation of hu-
man tenocytes. Tenocytes treated with HMC-1 condi-
tioned media for 24 or 48 hours showed a significant
increase in cell survival/proliferation over untreated con-
trol samples (Figure 1). The mean ± SEM percent sur-
vival/proliferation in HMC-1 conditioned media treated
relative to control samples at 24 hours was 158.8 ± 2.4%
and at 48 hours was 226.6 ± 2.49%. HMC-1 sonicate also
enhanced the survival/proliferation of tenocytes, albeit
to a lesser degree (data not shown).
Patellar tendinopathy tissue expresses increased levels of
COX-2 compared with controls [12]. We have found by
qPCR analysis and western blotting that HMC-1 condi-
tioned media significantly enhanced the mRNA and pro-
tein expression of Cox-2 in monolayer cultures of human
tenocytes in a time-dependent manner (Figure 2A and 2B,
respectively). The Cox-2 levels peaked at 6 hours relative
to control, and declined by 24 hours. At 6 hours, the COX-
2 mRNA mean ± SEM quantity relative to control (RQ)
was 14.29 ± 1.146 and the Cox-2 protein mean ± SEM
fold-change relative to control was 5.119 ± 0.302. The
TGF-β1 receptor ALK5 kinase inhibitor, A83-01 (2 μM),significantly blocked COX-2 mRNA (mean ± SEM RQ
4.982 ± 0.8868) and Cox-2 protein expression (mean ±
SEM fold-change 2.300 ± 0.5147, P = 0.037) by tenocytes
in response to HMC-1 conditioned media as shown in
Figure 2C and 2D, respectively. As expected, exogenous
active human TGF-β1 (2 ng/ml) enhanced COX-2 expres-
sion by tenocytes, which also peaked at 6 hours (data not
shown). Additionally, the COX-2 mRNA and Cox-2 pro-
tein expression in response to exogenous TGF-β1 were al-
most entirely inhibited by A83-01 (Figure 2C,D).
Since Cox-2 is one of the major enzymes contributing
to the production of PGE2 and since PGE2 is a major in-
flammatory mediator in tendon [13], we used ELISA to
measured PGE2 levels in the conditioned media of teno-
cytes stimulated with mast cells. As shown in Figure 3,
treatment of tenocytes with the HMC-1 conditioned
media significantly enhanced the production of PGE2 by
human tenocytes compared with control untreated teno-
cytes (mean ± SEM 38.85 ± 3.951 pg/ml vs. 5.200 ±
0.6364 pg/ml). This increase in PGE2 production was
shown to be dependent on both TGF-β1 and cyclooxygen-
ase, since both A83-01 and indomethacin significantly re-
duced PGE2 production by tenocytes in response to
treatment with mast cell conditioned media (mean ± SEM
12.83 ± 1.226 pg/ml and 6.650 ± 0.9078 pg/ml, respect-
ively), as shown in Figure 3.
PGE2 has been shown to downregulate type I collagen
expression [14] and tendinopathic or injured tendons
demonstrate a lower concentration of type I collagen
than healthy tendon, and a reduced load-bearing cap-
acity [15]. Our qPCR analysis revealed that addition of
AC D
B
Figure 2 Transforming growth factor beta-1 contributes to a mast cell-induced increase in COX-2 mRNA and protein expression by
human tenocytes. Tenocytes were cultured in the presence or absence of HMC-1 conditioned media (cond med), recombinant active
transforming growth factor beta-1 (TGF-β1), and A83-01 for the indicated times. Quantitative polymerase chain reaction and western blots show
increased cyclooxygenase COX-2 mRNA (A) and protein (B) in response to HMC-1 conditioned media. A83-01 reduced COX-2 mRNA (C) and
Cox-2 protein (D) by tenocytes in response to treatment with mast cell conditioned media or TGF-β1 for 6 hours. Data represent mean ± standard
error of the mean of at least three independent experiments, each run in triplicate. Mann–Whitney U test. *P = 0.022, **P = 0.0037.
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matrix significantly reduced COL1A1 mRNA by teno-
cytes relative to untreated cells, as shown in Figure 4A
(mean ± SEM RQ 0.5624 ± 0.04386 at 24 hours and
0.4356 ± 0.02135 at 48 hours). Exogenous addition of
PGE2 (5 μM) to tenocytes in the three-dimensional colla-
gen matrix independently reduced COL1A1 expression by
tenocytes relative to control, both at 24 hours (mean ±
SEM RQ 0.3065 ± 0.02276) and at 48 hours (mean ± SEM
RQ 0.3999 ± 0.04437) as shown in Figure 4A. Next, we ex-
amined the role of PGE2 in mast cell-mediated downregu-
lation of COL1A mRNA. We show that under conditions
where production of PGE2 both in mast cells and tencytes
were substantially blocked with indomethacin, Indo MCS
(the sonicate generated from indomethacin-treated mast
cells) did not have any effect on COL1A1 expression bytenocytes relative to control untreated cells (refer to
Methods for how Indo MCS was generated). The mean ±
SEM COL1A1 RQ was 1.116 ± 0.0802 at 24 hours and
0.9298 ± 0.04274 at 48 hours, as shown in Figure 4B. Im-
munofluorescent staining for type I procollagen (Figure 5)
revealed that tenocytes treated with mast cell conditioned
media for 24 hours produced significantly less type I pro-
collagen compared with control tenocytes. Mean arbitrary
fluorescence intensity units were 0.03541 ± 0.0011 for cells
treated with HMC-1 conditioned media versus 0.07719 ±
0.0019 for control samples. A representative immuno-
fluorescence image is shown in Figure 5. These data
demonstrate that HMC-1 mast cells modulate collagen
expression by tenocytes through PGE2-mediated events.
In vitro, contraction of the three-dimensional collagen
matrix by fibroblasts has been widely used as a model
Figure 3 Mast cell-induced prostaglandin E2 production by
human tenocytes is mediated through transforming growth
factor beta-1. Tenocytes were stimulated with HMC-1 conditioned
media (cond media) with or without indomethacin (2 μM) or A83-
01 (2 μM) for 6 hours. Media were removed, cells were washed
three times with phosphate-buffered saline, and incubated with a
fresh serum-free media for 24 hours. Enzyme-linked immunosorb-
ent assay measured the prostaglandin E2 (PGE2) concentration in
tenocyte-conditioned media. Data represents mean ± standard
error of the mean of at least three separate experiments. One-way
analysis of variance, P <0.001. *Statistically significant Bonferroni
post-hoc tests of P <0.01.
Figure 4 Mast cell-induced modulation of collagen expression
by human tenocytes is mediated through prostaglandin E2.
Tenocytes cultured in a three-dimensional collagen matrix were
stimulated with mast cell sonicate (MCS), prostaglandin E2 (PGE2,
5 μM), or sonicate generated from indomethacin-treated mast cells
(Indo MCS). Quantitative polymerase chain reaction analysis shows
COL1A1transcription levels by tenocytes in response to MCS and
PGE2 (A), and MCS versus Indo MCS (B). *P <0.001.
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Using this model, we found that MCS significantly en-
hanced the contraction of a three-dimensional collagen
lattice in a time-dependent manner (Figure 6). HMC-1
mast cells and the HMC-1 conditioned media also en-
hanced contraction in the same system (data not shown).
Exogenous recombinant active human TGF-β1 independ-
ently enhanced tenocyte-mediated collagen matrix con-
traction in a time-dependent manner (Figure 6). Inhibition
of the TGF-β1 activity with A83-01 (2 μM) almost com-
pletely abrogated the increase in matrix contraction in re-
sponse to MCS and TGF-β1. These findings indicate that
mast cell-derived TGF-β1 mediates collagen remodeling
by tendon fibroblasts.
MMPs play significant roles in tissue remodeling and
wound healing [17,18]. We found that MCS significantly
enhanced the expression of MMP1 and MMP7 in human
tenocytes (Figure 7A,B). Although exogenous addition of
active human TGF-β1 to tenocyte culture independently
enhanced MMP7 mRNA expression by tenocytes, A83-01
did not reduce the observed increase in MMP1 or MMP7
expression in response to HMC-1 sonicate (data not
shown). However, blocking MMP activities with a pan-
MMP inhibitor, batimastat, significantly inhibited mastcell-mediated contraction of the three-dimensional colla-
gen lattice in a concentration-dependent and time-
dependent manner as shown in Figure 7C. These results
suggest that the observed increase in matrix remodeling
in response to HMC-1 sonicate is due in part to induction
of MMP activities.
Discussion
Mast cells are significant players in many degenerative
and fibrotic disorders, with the capacity to directly influ-
ence fibroblasts, which coordinate the production and
remodeling of the extracellular matrix. In the current
study, we explored whether mast cells could contribute
*Control              cond media
Figure 5 Mast cells reduce type I procollagen protein expression by tenocytes. Immunofluorescent staining for type I procollagen protein
in a monolayer of tenocytes stimulated with HMC-1 conditioned media (cond media) for 24 hours. The immunofluorescent images were analyzed
for intensity of procollagen immunoreaction using the open source software CellProfiler and data are presented as mean arbitrary fluorescence
intensity units (a.u.). Representative immunofluorescent images of control versus conditioned media-treated tenocytes are shown. Data represent
mean ± standard error of the mean of at least three separate experiments, each run in triplicate. Mann–Whitney U test, *P <0.001.
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nopathy, including expression of proinflammatory or fi-
brotic substances [19], tendon hypercellularity [20], and
remodeling or degradation of the extracellular matrix [21].
We found that human mast cells enhanced tenocyte
survival/proliferation and increased their production of
the inflammatory mediator PGE2, which decreased the
production of type I collagen by tendon fibroblasts. In
addition, we found that mast cells enhanced the contrac-
tion and remodeling of a three-dimensional collagen
matrix by tenocytes, processes that were mediated by
TGF-β1 and MMPs. Since these mechanisms have been
implicated in the pathophysiology of tendinopathy, our re-
sults may be of relevance to understanding the develop-
ment of this condition.
Increased fibroblast proliferation has been reported in a
number of different fibrotic disorders, and mast cells have
been shown to contribute to this phenomenon in the skin,
lung and other organs [22]. We have shown in this study
that HMC-1 conditioned medium enhanced the survival/
proliferation of human tenocytes, a cell type whose densityis substantially increased in chronically injured tendon
[23]. This effect of mast cells on tenocytes was not unex-
pected, since mast cells carry a number of different media-
tors and growth factors that could potentially enhance cell
proliferation through several mechanisms, including mast
cell tryptase [24], heterotypic cell–cell adhesion and
interleukin-4 [25], and histamine [26].
Enhanced expression of COX-2 and increased PGE2
have been detected in tendinopathy [27]. Although
mechanical loading of tendon is believed to enhance the
expression of COX-2 and the subsequent production of
PGE2 by tendon cells [28], the role of inflammation per
se as a contributing factor to these events is controver-
sial [29]. Our finding that human mast cells enhanced
the expression of Cox-2 and increased the production of
PGE2 in tendon fibroblasts is in line with previous re-
sults using a variety of human fibroblast cell types [30].
Mast cells contain various growth factors, cytokines, and
proteases that could potentially mediate Cox-2 produc-
tion by fibroblasts, and TGF-β1 is one such cytokine.
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Figure 6 Mast cell-induced contraction of a three-dimensional collagen matrix is mediated through transforming growth factor beta-1.
Tenocytes embedded in a three-dimensional collagen gel were stimulated with mast cell sonicate (MCS) or active transforming growth factor
beta-1 (TGF-β1), in the presence or absence of A83-01. Data represent mean ± standard error of the mean of at least three separate experiments,
each run in triplicate. Two-way analysis of variance followed by Bonferroni’s post-hoc test was used for comparisons. P <0.001 for days 2 to 4 for
the following group comparisons: control versus MCS, MCS versus MCS + A83-01, control versus TGF-β1, and TGF-β1 versus TGF-β1 + A83-01.
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the inflammatory mediator PGE2 by human tenocytes.
Tenocytes treated with an inhibitor (A83-01) of the
TGF-β1 receptor (ALK5) showed a significant reduction
in COX-2 expression and PGE2 production in response
to mast cells. We know from our own unpublished ob-
servations and those of others that HMC-1 mast cells
constitutively express TGF-β1mRNA [31] and that the
TGF-β1protein is constitutively present in the conditioned
media of HMC-1 cells. Although mast cells contain other
inflammatory mediators that could enhance Cox-2 pro-
duction by fibroblasts [30], our findings implicate TGF-β1
as a mast cell-derived cytokine, which significantly en-
hanced the production of Cox-2 and PGE2 by tendon fi-
broblasts. This increase in PGE2 production in response to
mast cells could adversely affect collagen synthesis and the
subsequent healing response in tendons.
Understanding the production and remodeling of the
extracellular matrix, in particular collagen, is of rele-
vance to the etiology of degenerative or fibroticdisorders such as tendinopathy. We have shown here
that HMC-1 sonicate significantly reduced COL1A1
mRNA transcription and type I procollagen protein in
tenocytes, both in a three-dimensional collagen matrix
and in a monolayer cell culture. This result is in line
with the findings that MSC reduced collagen synthesis
by peritoneal and lung fibroblasts [32]. In contrast to
our findings, Gruber and colleagues showed that MSC
enhanced COL1A1 expression by skin fibroblasts [33].
Differences in the experimental conditions and hetero-
geneity in fibroblast responses could perhaps explain the
different findings in the two studies.
Mast cells are known to play a significant role in tissue
remodeling, healing, and fibrosis through their effect on fi-
broblasts. The three-dimensional fibroblast-populated col-
lagen matrix has been widely used as a model system to
study the contractile remodeling of extracellular matrix by
fibroblasts during tissue healing. In this study, we show
that the addition of MSC to a tenocyte populated collagen



























Figure 7 Matrix metalloproteinases contribute to the mast cell-induced contraction of tenocyte populated collagen matrices. Tenocytes
embedded in collagen matrices were stimulated with mast cell sonicate (MCS) for the indicated times and RNA was extracted. The quantitative
polymerase chain reaction analysis shows the mRNA expression of matrix metalloproteinases MMP1 (A) and MMP7 (B) by tenocytes in response
to MCS. Data represent mean ± standard error of the mean of at least three separate experiments, each run in triplicate (Student’s t test,
*P <0.025 relative to control). (C) A pan-MMP inhibitor (batimastat) added to the collagen gel inhibited contraction of the collagen matrix in
response to MCS in a concentration-dependent and time-dependent manner (P <0.001 for effects of both time and treatment).
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found that mast cells or MSC significantly enhanced
fibroblast-mediated contraction of a three-dimensional
collagen matrix [22]. Mast cell tryptase [34], MMPs [35],
intercellular gap junctions [36], and SCF/c-Kit heterotypic
cell–cell interactions [37] are amongst the various mecha-
nisms suggested to be involved in this process. However,
we have found that TGF-β1 is a major player in mediating
contraction of the tenocyte populated collagen matrix by
HMC-1 cells, since blocking of the TGF-β1 receptor with
A83-01 almost entirely inhibited matrix contraction.
The contraction of collagen matrix by fibroblasts is often
assumed to result from the differentiation of cells into
myofibroblasts, as gauged by their increased expression of
contractile smooth muscle actin [38]. Surprisingly, in our
system there was no increase in alpha smooth muscle
actin in response to MSC/conditioned media or TGF-β1
(data not shown), despite the fact that these substances in-
creased the rate of collagen matrix contraction. This
prompted us to examine whether the increased collagen
matrix contraction in response to HMC-1 could be due toincreased expression of MMPs that are known to play a
role in tendinopathies, including MMP1 [39] and MMP7
[40]. We found that both MMP1 and MMP7 mRNA in
tenocytes were increased in response to MSC. MMP1
plays an important role in breaking down the extracellular
matrix, and it specifically breaks down the interstitial type
I, type II, and type III collagens. Enhanced MMP1 expres-
sion could thus lead to matrix remodeling and collagen
matrix contraction. The collagen receptor α2β1 has been
linked to the increase in the induction of MMP1 and colla-
gen matrix contraction in cultures of primary human fi-
broblasts [41]. Although exogenous active TGF-β1 in our
hands enhanced MMP7 transcription by tenocytes, the in-
crease in MMP1 and MMP7 mRNA in response to mast
cells was not mediated throughTGF-β1. It has been shown
previously that MMP7 can enhance the bioavailability of
TGF-β1 in the extracellular matrix by releasing TGF-β1
from its bound complex with decorin [42]. A mast cell-
mediated increase in MMP7 expression and activity may
thus have led to the increased TGF-β1-induced collagen
matrix contraction. Other MMPs including MMP2 and
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mast cell-derived TGF-β1, leading to contraction of colla-
gen matrix [35]. Similar to the findings of Margulis and
colleagues [35], we have found that batimastat inhibited
mast cell-mediated contraction of collagen gel, prompting
us to conclude that MMP activity played a role in this
process.
Mast cells have been linked to many degenerative
conditions but currently no data are available on a pos-
sible role that mast cells might play in tendinopathy, al-
though increased mast cell numbers have been detected
in tendon biopsies from patients with tendinopathy. Al-
though mast cells have been reported to affect the func-
tion of different fibroblast cells throughout the body, we
are the first to report effects of mast cells on tendon
fibroblast gene expression and functions. It is important
to acknowledge, however, similar to any in vitro studies,
that our findings need to be confirmed with further
studies on clinical tendon specimens; co-localizing mast
cells with tenocytes, for example, in the tendon micro-
environment and analyzing the gene expression by teno-
cytes in these intact tendon tissues could further
strengthen our findings. In addition, a mouse model
that lacks mast cells would provide the ability to exam-
ine a possible influence of mast cells on tendon struc-
tural integrity and function.
In short, the present studies outline potential mecha-
nisms by which mast cells could contribute to the
pathogenesis of tendinopathy, and implicate the in-
volvement of TGF-β1, PGE2, and MMPs (notably
MMP1 and MMP7) in the response of tenocytes to mast
cells. Enhanced tenocyte survival/proliferation, in-
creased PGE2 production leading to downregulation of
type I collagen, and increased MMP production and ac-
tivity are amongst the potential mechanisms by which
mast cells could modulate tendon degeneration and re-
pair mechanisms. These findings suggest that therapies
aimed at inhibiting mast cells in tendon could be benefi-
cial in promoting recovery from tendon injury or
tendinopathy.Conclusion
These results demonstrate that inflammatory processes
mediated by mast cells regulate the function of human
tenocytes leading to reduction in collagen production
and increase in MMP expression by these cells. Overall,
these data, combined with our previous finding of in-
creased mast cell number in tendon biopsies from pa-
tients with patellar tendinopathy, suggest that mast cells
have a potential to mediate matrix remodeling of tendon
and contribute to tendon degradation. Further studies
are required to demonstrate a direct role of mast cells in
this process.Abbreviations
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